A lateral flow assay for rapid saliva fentanyl detection (sfentanyl)
Ended Project Grant Awarded Last action
- Award ID
- R43DA055415
- Recipient
-
Instanosis Inc. UEI CA5GQKREPCE4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $919,460
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Milford, DE, USA
Award details come from USAspending.gov.
Description
- Abstract
- Fentanyl is a major contributor to the opioid epidemic. Rapid identification of the causative drug as fentanyl is critical for prompt and appropriate administration of naloxone, and the right level of clinical care. From the public health perspective, rapid identification of fentanyl is also key to overdose surveillance, outbreak recognition and communication among healthcare professionals. The global market for point-of-care (POC) drug of abuse testing, fueled by the continued growth of illicit drug use worldwide, especially fentanyl and its derivatives, is estimated to be $3.8 billion in 2023, growing at a compound annual growth rate (cagr) of 5.4%. Oral fluid drugs of abuse testing market is estimated at $38.8 million in 2023. However, there is currently no FDA-approved or cleared rapid diagnostic for fentanyl screening at the POC. In this phase i sttr proposal, instanosis INC will partner with university of pennsylvania to develop and commercialize a rapid onsite screening diagnostics (sfentanyl) that can be deployed at the patient's side to quickly identify fentanyl in saliva. In sfentanyl, saliva is collected using swabs, quickly extracted and applied to the saliva lateral flow assay (sfentanyl) strip that can effectively detect 0.1 NG/ML fentanyl in saliva within 5 min. Readout is visual with naked eyes, with no need for external instruments. This rapid diagnostic tool meets the clinical needs of fentanyl detection at the
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $149,798 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $256,554 | |
| Amendment | $256,554 | |
| Original award | $256,554 |
Quick answers
Who received award R43DA055415?
R43DA055415 was awarded to Instanosis Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 1, 2022.
How much is award R43DA055415 worth?
$919,460 has been obligated on R43DA055415.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award